Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

Launched by GENERAL HOSPITAL OF SHENYANG MILITARY REGION · Nov 19, 2018

Keywords

ClinConnect Summary

This clinical trial is studying the safety of an anticoagulant medication called rivaroxaban for patients with non-valvular atrial fibrillation (AF) who have experienced an acute cerebral infarction (a type of stroke) or a transient ischemic attack (TIA). The trial aims to find out if starting rivaroxaban within 12 days after the onset of symptoms can help prevent further strokes without significantly increasing the risk of bleeding. This is important because there's still uncertainty about the best timing for starting such treatments in different patients, especially those with varying health conditions.

To participate in this study, individuals must be at least 18 years old and have had a recent stroke caused by AF, with a specific measure of stroke severity (NIHSS score of 15 or less). They should also be within 12 days of their stroke and have either had their first stroke or a previous stroke that did not leave them with major disabilities. Participants will be closely monitored throughout the trial to assess the medication's safety and effectiveness. If you or someone you know fits these criteria and is interested in learning more, please consider reaching out to the study team for additional information.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Over 18 years
• • 2. Acute cerebral infarction caused by non-valvular atrial fibrillation
• • 3. NIHSS score ≤ 15
• • 4. Within 12 days of onset
• • 5. first stroke onset or past stroke without obvious neurological deficit (mRS score≤1)
• • 6. Signed informed consent
• Exclusion Criteria:
• • 1. Hemorrhagic stroke or mixed stroke
• • 2. Patients with valvular atrial fibrillation or non-cardiogenic cerebral infarction
• • 3. Patients with severe infection or serious diseases
• • 4. Gastrointestinal bleeding or major operation within 3 months
• • 5. Planed cerebrovascular reconstruction or cardiac surgery within 3 months
• • 6. Planed major surgery within 3 months
• • 7. Participating in other clinical trials within 3 months
• • 8. Unsuitable for this trial assessed by research